Secukinumab for Psoriasis: Indefinite Maintenance Therapy
Secukinumab should be continued indefinitely as long-term maintenance therapy for your 28-year-old patient with psoriasis, with treatment sustained every 4 weeks after the initial 12-week loading phase. This is not a time-limited course but rather an ongoing treatment strategy.
Treatment Duration Framework
According to the 2019 Joint AAD-NPF Guidelines, psoriasis is a chronic disease requiring continuous biologic therapy to maintain disease control 1. The evidence demonstrates that:
- Initial loading phase: 300 mg at weeks 0,1,2,3, and 4
- Maintenance phase: 300 mg every 4 weeks starting at week 12 and continuing indefinitely 1
Critical finding: An RCT specifically assessed "as-needed" dosing after 12 weeks versus continuous every-4-week dosing and found that intermittent dosing was significantly less effective than continued regular dosing 1. This directly answers your question—stopping or reducing frequency leads to inferior outcomes.
Long-Term Efficacy Data
Real-world evidence supports indefinite continuation:
- Efficacy increases over time rather than plateaus: PASI 90 rates improved from 36% at week 16 to 71% at year 1,84.1% at year 4, and 90% at year 6 2
- PASI 100 (complete clearance) rates rose from 27.4% at week 16 to 67.1% at year 4 and 80.2% at year 7 2
- Treatment persistence rates in real-world practice: 88% at 1 year, 76.4% at 2 years, and 60.5% at 3 years 3
- Clinical trials demonstrate sustained efficacy up to 5 years with maintained dosing every 4 weeks 1, 4
When to Consider Stopping or Modifying
Do not arbitrarily stop after a set duration. However, consider these scenarios:
Dose Interval Extension (Not Cessation)
For patients achieving PASI ≤1 and maintaining PASI 90-100 response, extending intervals from every 4 weeks to every 8 weeks may be feasible 5:
- 75.4% maintained PASI 90 at 12 weeks with extended dosing
- 67.7% sustained PASI 90 at 36 weeks with extended dosing
- This is an optimization strategy, not discontinuation
Discontinuation Criteria
Stop treatment only if:
- Lack of efficacy: Failure to achieve adequate response after appropriate trial
- Adverse events: Serious adverse reactions (occurred in only 5 patients out of 769 in long-term studies—3 malignancies, 1 eosinophilic pneumonia, 1 pulmonary embolism) 2
- Patient preference: After informed discussion about disease relapse risk
Clinical Reasoning
The marital status mentioned in your question is irrelevant to treatment duration. However, if family planning becomes relevant:
- Secukinumab is acceptable for men attempting conception 1
- Safety during pregnancy/lactation is uncertain, requiring discussion if applicable
The 300 mg dose is superior to 150 mg (Level A recommendation) 1, so ensure your patient receives the higher dose for optimal long-term outcomes.
Practical Monitoring Approach
- Continue treatment as long as disease remains controlled
- Monitor PASI scores regularly (expect progressive improvement over years, not just months)
- Assess for adverse events at each visit (overall incidence is low: 19.9% in 6-year studies, mostly minor mucocutaneous fungal infections) 6
- Consider dose interval extension only after achieving PASI ≤1 with sustained PASI 90-100 response
Bottom line: Treat psoriasis like other chronic diseases requiring indefinite management (e.g., hypertension, diabetes). The evidence shows that stopping or reducing frequency after an arbitrary timeframe compromises outcomes 1.